Butalbital and Acetaminophen

drug-information.ru

|Butalbital and Acetaminophen

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Butalbital and Acetaminophen

Dosage Form: Tablets

Rx only

Code 613Z00                     Rev. 05/00

Butalbital and Acetaminophen Description

Butalbital and Acetaminophen is supplied in tablet form for oral administration.

Butalbital (5-allyl-5-isobutylbarbituric acid), a slightly bitter, white, odorless, crystalline powder, is a short to intermediate-acting barbiturate. It has the following structural formula:

C11H16N2O3                          MW = 224.26

Acetaminophen (4’-hydroxyacetanilide), a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula:

C8H9NO2                            MW = 151.17

Each Butapap tablet contains:

Butalbital …………………………………………….50 mg
         Warning: May be habit forming.
Acetaminophen ……………………………………...325 mg

In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, crospovidone, microcrystalline cellulose, povidone, pregelatinized starch, stearic acid.

Butalbital and Acetaminophen - Clinical Pharmacology

This combination drug product is intended as a treatment for tension headache.

It consists of a fixed combination of Butalbital and Acetaminophen. The role each component plays in the relief of the complex of symptoms known as tension headache is incompletely understood.

Pharmacokinetics

The behavior of the individual components is described below.

Butalbital: Butalbital is well absorbed from the gastrointestinal tract and is expected to distribute to most tissues in the body. Barbiturates in general may appear in breast milk and readily cross the placental barrier. They are bound to plasma and tissue proteins to a varying degree and binding increases directly as a function of lipid solubility.

Elimination of butalbital is primarily via the kidney (59% to 88% of the dose) as unchanged drug or metabolites. The plasma half-life is about 35 hours. Urinary excretion products include parent drug (about 3.6% of the dose), 5-isobutyl-5-(2,3-dihydroxypropyl) barbituric acid (about 24% of the dose), 5-allyl-5(3-hydroxy-2-methyl-l-propyl) barbituric acid (about 4.8% of the dose), products with the barbituric acid ring hydrolyzed with excretion of urea (about 14% of the dose), as well as unidentified materials. Of the material excreted in the urine, 32% is conjugated.

The in vitro plasma protein binding of butalbital is 45% over the concentration range of 0.5 to 20 mcg/mL. This falls within the range of plasma protein binding (20% to 45%) reported with other barbiturates such as phenobarbital, pentobarbital, and secobarbital sodium. The plasma-to-blood concentration ratio was almost unity indicating that there is no preferential; distribution of butalbital into either plasma or blood cells (See OVERDOSAGE for toxicity information.).

Acetaminophen: Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. The plasma half-life is 1.25 to 3 hours, but may be increased by liver damage and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug (See OVERDOSAGE for toxicity information.).

Indications and Usage for Butalbital and Acetaminophen

Butalbital and Acetaminophen Tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache.

Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.

Contraindications

This product is contraindicated under the following conditions:

  • Hypersensitivity or intolerance to any component of this product.
  • Patients with porphyria.

Warnings

Butalbital is habit-forming and potentially abusable. Consequently, the extended use of this product is not recommended.

Precautions

General

Butalbital and Acetaminophen Tablets should be prescribed with caution in certain special-risk patients, such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, or acute abdominal conditions.

Information for Patients

This product may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Such tasks should be avoided while taking this product.

Alcohol and other CNS depressants may produce an additive CNS depression, when taken with this combination product, and should be avoided.

Butalbital may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.

Laboratory Tests

In patients with severe hepatic or renal disease, effects of therapy should be monitored with serial liver and/or renal function tests.

Drug Interactions

The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.

Butalbital and Acetaminophen may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.

Drug/Laboratory Test Interactions

Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No adequate studies have been conducted in animals to determine whether acetaminophen or butalbital have a potential for carcinogenesis, mutagenesis or impairment of fertility.

Pregnancy

Teratogenic Effects: Pregnancy Category C

Animal reproduction studies have not been conducted with this combination product. It is also not known whether Butalbital and Acetaminophen can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. This product should be given to a pregnant woman only when clearly needed.

Nonteratogenic Effects

Withdrawal seizures were reported in a two-day-old male infant whose mother had taken a butalbital-containing drug during the last two months of pregnancy. Butalbital was found in the infant’s serum. The infant was given phenobarbital 5 mg/kg, which was tapered without further seizure or other withdrawal symptoms.

Nursing Mothers

Barbiturates and acetaminophen are excreted in breast milk in small amounts, but the significance of their effects on nursing infants is not known. Because of potential for serious adverse reactions in nursing infants from Butalbital and Acetaminophen, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of 12 have not been established.

Adverse Reactions

Frequently Observed: The most frequently reported adverse reactions are drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea, vomiting, abdominal pain, and intoxicated feeling.

Infrequently Observed: All adverse events tabulated below are classified as infrequent.

Central Nervous System: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness, sluggishness, seizure. Mental confusion, excitement or depression can also occur due to intolerance, particularly in elderly or debilitated patients, or due to overdosage of butalbital.

Autonomic Nervous System: dry mouth, hyperhidrosis.

Gastrointestinal: difficulty swallowing, heartburn, flatulence, constipation.

Cardiovascular: tachycardia.

Musculoskeletal: leg pain, muscle fatigue.

Genitourinary: diuresis.

Miscellaneous: pruritus, fever, earache, nasal congestion, tinnitus, euphoria, allergic reactions.

Several cases of dermatological reactions, including toxic epidermal necrolysis and erythema multiforme, have been reported.

The following adverse drug events may be borne in mind as a potential effect of the components of this product. Potential effects of high dosage are listed in the OVERDOSAGE section.

Acetaminophen: allergic reactions, rash, thrombocytopenia, agranulocytosis.

Drug Abuse and Dependence

Abuse and Dependence

Butalbital: Barbiturates may be habit-forming: Tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. The average daily dose for the barbiturate addict is usually about 1500 mg. As tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. As this occurs, the margin between an intoxication dosage and fatal dosage becomes smaller. The lethal dose of a barbiturate is far less if alcohol is also ingested. Major withdrawal symptoms (convulsions and delirium) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. Intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. Treatment of barbiturate dependence consists of cautious and gradual withdrawal of the drug. Barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. One method involves initiating treatment at the patient’s regular dosage level and gradually decreasing the daily dosage as tolerated by the patient.

Overdosage

Following an acute overdosage of Butalbital and Acetaminophen, toxicity may result from the barbiturate or the acetaminophen.

Signs and Symptoms

Toxicity from barbiturate poisoning includes drowsiness, confusion, and coma; respiratory depression; hypotension; and hypovolemic shock.

In acetaminophen overdosage: dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect. Renal tubular necroses, hypoglycemic coma and thrombocytopenia may also occur. Early symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion. In adults, hepatic toxicity has rarely been reported with acute overdoses of less than 10 grams, or fatalities with less than 15 grams.

Treatment

A single or multiple overdose with this combination product is a potentially lethal polydrug overdose, and consultation with a regional poison control center is recommended.

Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. Vomiting should be induced mechanically, or with syrup of ipecac, if the patient is alert (adequate pharyngeal and laryngeal reflexes). Oral activated charcoal (1 g/kg) should follow gastric emptying. The first dose should be accompanied by an appropriate cathartic. If repeated doses are used, the cathartic might be included with alternate doses as required. Hypotension is usually hypovolemic and should respond to fluids. Pressors should be avoided. A cuffed endotracheal tube should be inserted before gastric lavage of the unconscious patient and, when necessary, to provide assisted respiration. If renal function is normal, forced diuresis may aid in the elimination of the barbiturate. Alkalinization of the urine increases renal excretion of some barbiturates, especially phenobarbital.

Meticulous attention should be given to maintaining adequate pulmonary ventilation. In severe cases of intoxication, peritoneal dialysis, or preferably hemodialysis may be considered. If hypoprothrombinemia occurs due to acetaminophen overdose, vitamin K should be administered intravenously.

If the dose of acetaminophen may have exceeded 140 mg/kg, acetylcysteine should be administered as early as possible. Serum acetaminophen levels should be obtained, since levels four or more hours following ingestion help predict acetaminophen toxicity. Do not await acetaminophen assay results before initiating treatment. Hepatic enzymes should be obtained initially, and repeated at 24-hour intervals.

Methemoglobinemia over 30% should be treated with methylene blue by slow intravenous administration.

Toxic Doses (for adults)

Butalbital:                toxic dose       1 g    (20 tablets)
Acetaminophen:       toxic dose     10 g    (30 tablets)

USUAL DOSAGE

Oral: One or two tablets every four hours. Total daily dosage should not exceed 6 tablets.

Extended and repeated use of this product is not recommended because of the potential for physical dependence.

How is Butalbital and Acetaminophen Supplied

Butapap Tablets (Butalbital and Acetaminophen Tablets) 50 mg/325 mg are supplied in bottles of 100 tablets, NDC 46672-099-10, and in bottles of 500 tablets, NDC 46672-099-50. Each tablet contains butalbital 50 mg (Warning: May be habit forming) and acetaminophen 325 mg. Tablets are uncoated, white, capsule-shaped and are debossed “MIA/106” on the same side as the single-score.

Storage: Protect from light and moisture. Store at controlled room temperature, 15°C to 30°C (59°F to 86°F).

Dispense in a tight, light-resistant container with a child-resistant closure.

Rx only

Manufactured by:
MIKART, INC.
Atlanta, GA 30318

Rev. 05 / 00                 Code 6l3Z00


Butalbital and Acetaminophen (Butalbital and Acetaminophen)
PRODUCT INFO
Product Code 46672-099 Dosage Form TABLET
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
BUTALBITAL (BUTALBITAL) Active 50 MILLIGRAM  In 1 TABLET
ACETAMINOPHEN (ACETAMINOPHEN) Active 325 MILLIGRAM  In 1 TABLET
COLLOIDAL SILICON DIOXIDE Inactive  
CROSCARMELLOSE SODIUM Inactive  
CROSPOVIDONE Inactive  
MICROCRYSTALLINE CELLULOSE Inactive  
POVIDONE Inactive  
PREGELATINIZED STARCH Inactive  
STEARIC ACID Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color WHITE Score 2
Shape OVAL (CAPSULE-SHAPED) Symbol false
Imprint Code MIA;106 Coating false
Size 18mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 46672-099-10 100 TABLET In 1 BOTTLE None
2 46672-099-50 500 TABLET In 1 BOTTLE None

Revised: 12/2006





Where can I get more information about Butalbital and Acetaminophen ? We recommend to use www.Drugs.com

Typical mistypes for Butalbital and Acetaminophen
vutalbital and acetaminophen, nutalbital and acetaminophen, hutalbital and acetaminophen, gutalbital and acetaminophen, bytalbital and acetaminophen, bhtalbital and acetaminophen, bjtalbital and acetaminophen, bitalbital and acetaminophen, b8talbital and acetaminophen, b7talbital and acetaminophen, buralbital and acetaminophen, bufalbital and acetaminophen, bugalbital and acetaminophen, buyalbital and acetaminophen, bu6albital and acetaminophen, bu5albital and acetaminophen, butzlbital and acetaminophen, butslbital and acetaminophen, butwlbital and acetaminophen, butqlbital and acetaminophen, butakbital and acetaminophen, butapbital and acetaminophen, butaobital and acetaminophen, butalvital and acetaminophen, butalnital and acetaminophen, butalhital and acetaminophen, butalgital and acetaminophen, butalbutal and acetaminophen, butalbjtal and acetaminophen, butalbktal and acetaminophen, butalbotal and acetaminophen, butalb9tal and acetaminophen, butalb8tal and acetaminophen, butalbiral and acetaminophen, butalbifal and acetaminophen, butalbigal and acetaminophen, butalbiyal and acetaminophen, butalbi6al and acetaminophen, butalbi5al and acetaminophen, butalbitzl and acetaminophen, butalbitsl and acetaminophen, butalbitwl and acetaminophen, butalbitql and acetaminophen, butalbitak and acetaminophen, butalbitap and acetaminophen, butalbitao and acetaminophen, butalbital znd acetaminophen, butalbital snd acetaminophen, butalbital wnd acetaminophen, butalbital qnd acetaminophen, butalbital abd acetaminophen, butalbital amd acetaminophen, butalbital ajd acetaminophen, butalbital ahd acetaminophen, butalbital ans acetaminophen, butalbital anx acetaminophen, butalbital anc acetaminophen, butalbital anf acetaminophen, butalbital anr acetaminophen, butalbital ane acetaminophen, butalbital and zcetaminophen, butalbital and scetaminophen, butalbital and wcetaminophen, butalbital and qcetaminophen, butalbital and axetaminophen, butalbital and avetaminophen, butalbital and afetaminophen, butalbital and adetaminophen, butalbital and acwtaminophen, butalbital and acstaminophen, butalbital and acdtaminophen, butalbital and acrtaminophen, butalbital and ac4taminophen, butalbital and ac3taminophen, butalbital and aceraminophen, butalbital and acefaminophen, butalbital and acegaminophen, butalbital and aceyaminophen, butalbital and ace6aminophen, butalbital and ace5aminophen, butalbital and acetzminophen, butalbital and acetsminophen, butalbital and acetwminophen, butalbital and acetqminophen, butalbital and acetaninophen, butalbital and acetakinophen, butalbital and acetajinophen, butalbital and acetamunophen, butalbital and acetamjnophen, butalbital and acetamknophen, butalbital and acetamonophen, butalbital and acetam9nophen, butalbital and acetam8nophen, butalbital and acetamibophen, butalbital and acetamimophen, butalbital and acetamijophen, butalbital and acetamihophen, butalbital and acetaminiphen, butalbital and acetaminkphen, butalbital and acetaminlphen, butalbital and acetaminpphen, butalbital and acetamin0phen, butalbital and acetamin9phen, butalbital and acetaminoohen, butalbital and acetaminolhen, butalbital and acetamino-hen, butalbital and acetamino0hen, butalbital and acetaminopgen, butalbital and acetaminopben, butalbital and acetaminopnen, butalbital and acetaminopjen, butalbital and acetaminopuen, butalbital and acetaminopyen, butalbital and acetaminophwn, butalbital and acetaminophsn, butalbital and acetaminophdn, butalbital and acetaminophrn, butalbital and acetaminoph4n, butalbital and acetaminoph3n, butalbital and acetaminopheb, butalbital and acetaminophem, butalbital and acetaminophej, butalbital and acetaminopheh, utalbital and acetaminophen, btalbital and acetaminophen, bualbital and acetaminophen, butlbital and acetaminophen, butabital and acetaminophen, butalital and acetaminophen, butalbtal and acetaminophen, butalbial and acetaminophen, butalbitl and acetaminophen, butalbita and acetaminophen, butalbitaland acetaminophen, butalbital nd acetaminophen, butalbital ad acetaminophen, butalbital an acetaminophen, butalbital andacetaminophen, butalbital and cetaminophen, butalbital and aetaminophen, butalbital and actaminophen, butalbital and aceaminophen, butalbital and acetminophen, butalbital and acetainophen, butalbital and acetamnophen, butalbital and acetamiophen, butalbital and acetaminphen, butalbital and acetaminohen, butalbital and acetaminopen, butalbital and acetaminophn, butalbital and acetaminophe, ubtalbital and acetaminophen, btualbital and acetaminophen, buatlbital and acetaminophen, butlabital and acetaminophen, butablital and acetaminophen, butalibtal and acetaminophen, butalbtial and acetaminophen, butalbiatl and acetaminophen, butalbitla and acetaminophen, butalbita land acetaminophen, butalbitala nd acetaminophen, butalbital nad acetaminophen, butalbital adn acetaminophen, butalbital an dacetaminophen, butalbital anda cetaminophen, butalbital and caetaminophen, butalbital and aectaminophen, butalbital and acteaminophen, butalbital and aceatminophen, butalbital and acetmainophen, butalbital and acetaimnophen, butalbital and acetamniophen, butalbital and acetamionphen, butalbital and acetaminpohen, butalbital and acetaminohpen, butalbital and acetaminopehn, butalbital and acetaminophne, bbutalbital and acetaminophen, buutalbital and acetaminophen, buttalbital and acetaminophen, butaalbital and acetaminophen, butallbital and acetaminophen, butalbbital and acetaminophen, butalbiital and acetaminophen, butalbittal and acetaminophen, butalbitaal and acetaminophen, butalbitall and acetaminophen, butalbital and acetaminophen, butalbital aand acetaminophen, butalbital annd acetaminophen, butalbital andd acetaminophen, butalbital and acetaminophen, butalbital and aacetaminophen, butalbital and accetaminophen, butalbital and aceetaminophen, butalbital and acettaminophen, butalbital and acetaaminophen, butalbital and acetamminophen, butalbital and acetamiinophen, butalbital and acetaminnophen, butalbital and acetaminoophen, butalbital and acetaminopphen, butalbital and acetaminophhen, butalbital and acetaminopheen, butalbital and acetaminophenn, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved